Roche https://validator.w3.org/feed/docs/rss2.html Bladder (urothelial) cancer Tecentriq<sup class="registered-mark">®</sup> Tecentriq<sup class="registered-mark">®</sup> Slideshow Button Alecensa<sup class="registered-mark">®</sup> DLBCL Slideshow Button 2 Kadcyla<sup class="registered-mark">®</sup> POLIVY<sup class="registered-mark">®</sup> Gazyva<sup class="registered-mark">®</sup> Columvi<sup class="registered-mark">®</sup> Liver cancer (hepatocellular carcinoma) Erivedge<sup class="registered-mark">®</sup> Blood Cancer ROZLYTREK<sup class="registered-mark">®</sup> Registration Basal cell carcinoma (BCC) Relapsed Non-small cell lung cancer (NSCLC) Benign Aggressive White blood cells Unfunded treatment Triple negative breast cancer (TNBC) Subcutaneous injection Subcutaneous Refractory Platelets Non-PHARMAC funded medicines Non-Hodgkin’s lymphoma Monoclonal antibody Monoclonal antibodies iNHL Induction treatment Indolent CLL Carcinoma Advanced NSCLC Breast Cancer Treatment providers Skin Cancer Lung Cancer Click on the relevant cancer type to learn about Roche cancer treatments for your type of cancer. Phesgo<sup class="registered-mark">®</sup> PHARMAC Glossary Zelboraf<sup class="registered-mark">®</sup> & Cotellic<sup class="registered-mark">®</sup> combination therapy Perjeta<sup class="registered-mark">®</sup> Blog Chronic lymphocytic leukaemia